비만치료제 의약품이상사례 실마리정보 검색

Signal detection of obesity treatments adverse drug reaction using Korea Adverse Event Reporting System Database

The objective of this study was detection of signals corresponding to adverse drug reactions following obesitytreatments using the Korea Adverse Event Reporting System Database. Eight obesity drugs recommended in the obesitytreatment guidelines were analyzed for adverse events reported from January 2009 to December 2018. The ratio ofreporting, ratio of reporting odds, and information components were analyzed, and the case in which all three criteria weremet was detected as a signal. Signals that were not included in the label were classified as new signals. In the case ofphentermine, phendimetrazine, diethylpropion, lorcaserin, mazindol, liraglutide, or listat, and naltrexone/bupropion, therewere 2, 10, 5, 6, 1, 10, 7, and 5 confirmed cases of signal detection, respectively. No new signal was detected forphentermine and mazindol adverse events. For phendimetrazine, diethylpropion, lorcaserin, liraglutide, orlistat, andnaltrexone/bupropion, there were 5, 2, 1, 7, 4, and 1 cases of new signals, respectively. This study assessed signal detectionrelated to adverse events for eight obesity drugs. It is necessary to consider whether permission information should bereflected through continuous research on the detection of signals that are not reflected in the existing permits.